Ann Cardiol Cardiovasc Med | Volume 3, Issue 3 | Review Article | Open Access

Chemical Characteristics of Direct FXa Inhibitors Registered for Atrial Fibrillation

Alexandre Bridoux^1*, Michel Meyer Samama^2,3 and Shaker A Mousa¹

¹Pharmaceutical Research Institute, USA ²Biomnis Laboratories R&D, France ³Hospital Group Broca-Cauchin-Hôtel-Dieu, France

^*Correspondance to: Alexandre Bridoux 

Fulltext PDF

Abstract

This review publication highlights chemical characteristics of several direct factor Xa inhibitors that have been recently approved for Atrial Fibrillation (AFIB) and prevention and treatment of Venous Thromboembolic (VTE) disorders. Our goal is to help clinicians clarify the differences between these inhibitors by presenting the chemist and clinician points of view. A summary of the development phase (between the years 2000 to 2010) of the factor Xa inhibitors by the major pharmaceutical companies is reported followed by a focus on some important structure-activity relationships and pharmacological properties of Apixaban, Rivaroxaban, and Edoxaban. To go beyond what is found in the literature, we discuss and rationalize clinical pharmacological properties by reviewing the chemical characteristics of each molecule together with their pharmacological effects.

Keywords:

Direct factor Xa inhibitor; Anticoagulant; Apixaban; Rivaroxaban; Edoxaban

Citation:

Bridoux A, Samama MM, Mousa SA. Chemical Characteristics of Direct FXa Inhibitors Registered for Atrial Fibrillation. Ann Cardiol Cardiovasc Med. 2019; 3(3): 1028..